The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of neuronal dopamine production in the brain. Oral therapies primarily augment the dopaminergic pathway. As the disease progresses, more continuous delivery of therapy is commonly needed. Deep brain stimulation (DBS) has become an effective therapy option for several different neurologic and psychiatric conditions, including PD. It currently has US Food and Drug Administration approval for PD and essential tremor, as well as a humanitarian device exception for dystonia and obsessive-compulsive disorder. For PD treatment, it is currently approved specifically for those patients suffering from complications of pharmacotherapy, including motor fluctuations or dyskinesias, and a disease process of at least 4 years of duration. Studies have demonstrated superiority of DBS and medical management compared to medical management alone in selected PD patients. Optimal patient selection criteria, choice of target, and programming methods for PD and the other indications for DBS are important topics that continue to be explored and remain works in progress. In addition, new hardware options, such as different types of leads, and different software options have recently become available, increasing the potential for greater efficacy and/or reduced side effects. This review gives an overview of therapeutic management in PD, specifically highlighting DBS and some of the recent changes with surgical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642 · cited 1×
“A myriad of symptoms, collectively termed “nonmotor” symptoms, may occur in association with these classic PD symptoms and include orthostatic hypotension, constipation, urinary changes, depression, psychosis, sleep disorders, and cognitive dysfunction, among others.(6,7) Some of these symptoms can be directly impacte…”
Cited by
Materials for flexible bioelectronic systems as chronic neural interfaces
Song, E., Li, J., Won, S. M., Bai, W., & Rogers, J. A. (2020) · Nature Materials · doi:10.1038/s41563-020-0679-7 · Cited by 498
“c, Top: scanning electron microscope image of a reticular bioactive scaffold with (1) kinked Si-NW FETs (80 nm diameter), (2) metallic interconnects (Cr/Pd/Cr) and (3) SU-8 encapsulation (1 μm wide, ~1 μm”
BackgroundWireless and battery-free technologies for neuroengineering
Won, S. M., Cai, L., Gutruf, P., & Rogers, J. A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00683-3 · Cited by 360
Recent Advances in Materials, Devices, and Systems for Neural Interfaces
Won, S. M., Song, E., Zhao, J., Li, J., Rivnay, J., & Rogers, J. A. (2018) · Advanced Materials · doi:10.1002/adma.201800534 · Cited by 206
Rainey, S., & Erden, Y. J. (2020) · Science and Engineering Ethics · doi:10.1007/s11948-020-00240-2 · Cited by 32
Metadata
- Authors
- Fang, J. Y., & Tolleson, C.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-03
- Volume
- Volume 13
- Pages
- 723-732
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2591639181
- Cited by
- 80
- References
- 3
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.